NASDAQ (usa) arrow 6715.56 -12.11 -0.18%
FTSE 100 (london) arrow 7487.96 -5.12 -0.07%
DAX (german) arrow 13465.51 235.94 1.78%
NIKKEI 225 (japan) arrow 22420.08 408.47 1.86%
Hang - Seng (hong kong) arrow 28594.06 348.52 1.23%
NIFTY - 50 (india)
Straits Times (singapore) arrow 3391.61 17.53 0.52%
KOSPI (korea) arrow 2556.47 33.04 1.31%
All Ordinaries (australia) arrow 6005.30 28.90 0.48%
BOVESPA (brazil) arrow 74092.76 -215.73 -0.29%

Adamas Pharmaceuticals Inc (NASDAQ: ADMS)

 
ADMS Technical Analysis
1
As on N/A ADMS Share Price closed @ N/A and we RECOMMEND N/A for LONG-TERM with Stoploss of N/A & N/A for SHORT-TERM with Stoploss of N/A we also expect STOCK to react on Following IMPORTANT LEVELS.
 
 

ADMS Share Price

Open N/A Change Price %
High N/A 1 Day N/A N/A
Low N/A 1 Week N/A N/A
Close N/A 1 Month N/A N/A
Volume N/A 1 Year N/A N/A
52 Week High N/A | 52 Week Low N/A
 
NASDAQ USA Most Active Stocks
XELA 0.55 34.15%
AAPL 159.78 -1.14%
AMD 111.13 -4.63%
SOFI 12.76 -4.06%
NVDA 223.24 -4.48%
MSFT 288.49 -2.66%
SNDL 0.48 4.35%
BBIG 3.01 2.73%
INTC 51.00 -1.81%
PIXY 1.55 -9.88%
 
NASDAQ USA Top Gainers Stocks
CETXW 0.02 100.00%
ZJZZT 37.50 79.86%
AKICW 0.77 60.42%
ZWZZT 22.00 46.67%
SRRA 22.68 46.23%
DBGIW 0.49 40.00%
APM 2.25 38.89%
APM 2.25 38.89%
APM 2.25 38.89%
APM 2.25 38.89%
 
NASDAQ USA Top Losers Stocks
PTRAW 0.23 -89.59%
DSKEW 0.01 -66.67%
IKNX 19.52 -42.42%
PAVMW 0.03 -40.00%
OTLKW 0.03 -40.00%
XBIOW 1.30 -35.00%
ROVRW 1.30 -34.34%
STMP 0.02 -33.33%
STMP 0.02 -33.33%
IMRNW 0.20 -33.33%
 
 
ADMS
Daily Charts
ADMS
Intraday Charts
Whats New @
Bazaartrend
ADMS
Free Analysis
 
ADMS Important Levels Intraday
RESISTANCE
RESISTANCE
RESISTANCE
RESISTANCE
RESISTANCE
RESISTANCE
RESISTANCE
RESISTANCE
 
ADMS Target for Month January
4th UP TARGET
3rd UP TARGET
2nd UP TARGET
1st UP TARGET
1st DOWN TARGET
2nd DOWN TARGET
3rd DOWN TARGET
4th DOWN TARGET
 
ADMS Weekly Target
4th UP TARGET
3rd UP TARGET
2nd UP TARGET
1st UP TARGET
1st DOWN TARGET
2nd DOWN TARGET
3rd DOWN TARGET
4th DOWN TARGET
 
ADMS Target for Year 2022
4th UP TARGET
3rd UP TARGET
2nd UP TARGET
1st UP TARGET
1st DOWN TARGET
2nd DOWN TARGET
3rd DOWN TARGET
4th DOWN TARGET
 
 
ADMS Other Details
Segment EQ
Market Capital 371006848.00
Sector Healthcare
Industry Drug Manufacturers-Specialty & Generic
Offical website >
 
ADMS Address
ADMS
 
ADMS Latest News
 
Your Comments and Response on Adamas Pharmaceuticals Inc
 
ADMS Business Profile
Adamas Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders in the United States. It offers GOCOVRI, an extended release capsule for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications, as well as an adjunctive treatment to levodopa/carbidopa in patients with Parkinson's disease experiencing OFF episodes; and OSMOLEX ER, an extended release tablet to treat Parkinson's disease and drug-induced extrapyramidal reactions in adult patients. The company is also developing ADS-4101, which has completed two Phase 1b studies for treating partial onset seizures in patients with epilepsy. In addition, it offers NAMZARIC and NAMENDA XR, a memantine hydrochloride extended release and donepezil hydrochloride capsules for the treatment of moderate to severe dementia of an Alzheimer's type. The company was formerly known as NeuroMolecular Pharmaceuticals, Inc. and changed its name to Adamas Pharmaceuticals, Inc. in July 2007. Adamas Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California. Address: 1900 Powell Street, EmeryVille, CA, United States, 94608
 
2005-2021 BazaarTrend.com All rights reserved.

Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service